Today: 20 May 2026
Browse Category

NASDAQ:ERNA 29 October 2025 - 12 May 2026

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Stock’s 58% Jump Shows How Fast a Tiny Biotech Can Reprice on Ovarian-Cancer Hopes

Ernexa Therapeutics shares jumped 58.5% to $11.43 Tuesday after renewed investor focus on its preclinical ovarian-cancer therapy ERNA-101, following a May 11 investor event. Trading volume reached about 18.85 million shares. The company reported $8.3 million in cash as of April 30, less than needed for its 12-month plan, and may use an at-the-market stock sale to raise funds.
Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Ernexa Therapeutics said its ERNA-101 cell therapy plus PD-1 blockade cleared tumors and achieved 100% long-term survival in preclinical ovarian cancer models. Shares jumped about 60% after the announcement, trading between $3.70 and $7.66. The company remains preclinical and recently completed a 1-for-25 reverse stock split to maintain its Nasdaq listing.
Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics shares jumped nearly 50% to $1.80 intraday on October 29, 2025, after announcing a manufacturing partnership with Cellipont Bioservices to advance its ovarian cancer cell therapy, ERNA-101, toward clinical trials. Trading volume surged. Despite the rally, ERNA stock remains down about 58% in 2025 and 89% year-on-year after previous setbacks and a reverse stock split.

Stock Market Today

  • L3Harris Technologies Stock Seen Undervalued Despite Recent Pullback
    May 20, 2026, 7:21 AM EDT. L3Harris Technologies (LHX) shares have pulled back 12% over the past month, trading around $308, but remain up 35.8% over the last year. A Discounted Cash Flow (DCF) model estimates an intrinsic share value near $412, indicating the stock is trading at a roughly 25% discount. The aerospace and defense firm's latest free cash flow is $2.59 billion, with projections rising to $4.02 billion by 2030. L3Harris's valuation score of 5 out of 6 suggests a disconnect between market price and intrinsic value, prompting investors to consider longer-term cash flow potential amid sector contract activities and defense spending shifts.

Latest articles

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

InMed Pharmaceuticals (INM) Stock Doubled on Mentari Merger — Why the Rally Is Already Being Tested

20 May 2026
InMed Pharmaceuticals shares fell 14.4% to $1.37 in early pre-market trading Wednesday, after surging 135% Tuesday on news of an all-stock merger with Mentari Therapeutics and a planned $290 million private placement. Pre-merger InMed shareholders are expected to own about 1.51% of the combined company, which will operate as Mentari Therapeutics and focus on migraine drug development.
Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut

Micware Shares Swing Pre-Market After 26% Drop on Nasdaq Debut

20 May 2026
Micware shares jumped 97.7% to $9.33 in premarket U.S. trading Wednesday, rebounding above last week’s $8 IPO price after closing Tuesday at $4.72. A new SEC filing showed Toyota owns 11.6% of Micware’s ordinary shares. The Japanese automotive software firm raised $22.8 million in its Nasdaq debut last week.
Dow edges up while Nasdaq falls as bond worries drag on

Futures Edge Higher Ahead of Nvidia Earnings as Wall Street Watches Key Report

20 May 2026
Nasdaq 100 futures rose 0.73% and S&P 500 futures gained 0.35% ahead of Wednesday’s open, with Nvidia set to report earnings after the close. Options markets priced in a 6.5% swing for Nvidia, equal to about $355 billion in market value. In premarket trading, Nvidia shares rose 1.84%, while Micron, Intel, and AMD also advanced. Fed minutes are due at 2:00 p.m. EDT.
Go toTop